TrialOnvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Trial details
- Registry ID
- NCT03414034
- Phase
- Phase 2
Drug research
Abiraterone
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034 | Cardiff Oncology | Phase 2 | Completed | 2023-10-16Actual |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 | MacroGenics | Phase 2 | Terminated | 2024-07-04Actual |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 | Exelixis | Phase 3 | Enrolling by invitation | 2030-05-31Estimated |
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Trial details
- Registry ID
- NCT05551117
- Phase
- Phase 2
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Trial details
- Registry ID
- NCT07620574
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |